Since CXCR1/CXCR2 are also activated by CXCL6 and MIP2, we may not formally exclude that altered levels of these two chemokines are also involved in the development of myelofibrosis in our model and that their levels where normalized by treatment with Reparixin. The gene discussed is CXCR2; the disease is myelofibrosis.